Novartis partnered with Qualcomm Incorporated through its subsidiary, Qualcomm Life, in digital invention with the Breezhaler(TM) inhaler device to treat Chronic Obstructive Pulmonary Disease (COPD). Qualcomm Life will offer the technology solution for the connectivity of the next generation of the Breezhaler(TM) inhaler, a device used for Novartis’ assortment of COPD treatments.
Qualcomm Enters Health Business to Facilitate Breezhaler(TM) in Connectivity Inhaler Device
This next generation of the Breezhaler(TM) inhaler will facilitate patients to have access to their own information on the use of their inhaler in near future. The small, one-use and low power component confined within the inhaler device can identify and report usage, the time that the inhaler is used, along with other related information for patients and doctors. The module then propels the data to the patient’s smartphone and a Novartis COPD mobile application, which sends the data to the cloud, letting patients and potentially their healthcare providers to monitor their COPD. The joined device will be ready for use by patients, with no association required. COPD affects approximately 210 million people globally and is the third leading cause of death.
“Novartis supports patients being empowered to make it easier for them to manage their chronic conditions.”
Said David Epstein, Head Novartis Pharmaceuticals.
“By enabling near real time data capture from the patient and the connected Breezhaler(TM) device, patients can monitor their own adherence to the medication they take which is vital to their health outcomes.”
Qualcomm Life aims to organize health care to improve lives and develop the competencies of medical devices. Qualcomm Life is focused on device connectivity and data management, sanctioning medical device companies to provide wireless health fast and easily to those who need it.
Novartis intends to be the first company in respiratory medicine to offer a completely integrated, connected delivery device to provide a seamless, easy to use and simple experience for patients. Novartis provides novel healthcare solutions that address the developing needs of patients and societies. The Breezhaler device permits patients to hear, feel and see that they have taken the full dose properly.